A Phase 1 Study to Evaluate the Safety and Immunogenicity of an Intranasal Live Attenuated Respiratory Syncytial Virus (RSV) Vaccine in Healthy Adults
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Meissa Vaccines, Inc.
- Enrollment
- 20
- Locations
- 1
- Primary Endpoint
- Serious adverse events (SAEs)
Study Overview
Brief Summary
This study evaluates an investigational vaccine designed to protect humans against infection with respiratory syncytial virus (RSV). The investigational vaccine (MV-012-968) is administered as drops in the nose. This study specifically analyzes the safety of, and the immune response to, the vaccine when administered to healthy non-pregnant adults between the ages of 18 and 40 years.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 40 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Adult 18-40 years of age
- •In good health based on review of the medical record, history, and physical examination, without evidence of chronic disease
- •RSV 'sero-low' from a pre-vaccination serum sample
- •Signed informed consent form
Exclusion Criteria
- •Occupational or household exposure to children < 5 years of age, or to immunocompromised individuals
- •Prior receipt of an investigational RSV vaccine
- •Women who are pregnant, lactating, or unwilling to take effective measures to prevent pregnancy for at least 3 months after vaccination
- •Any other reason the Investigator considers exclusionary
Arms & Interventions
RSV Vaccine: Dosage Group #1
Participants in this group will receive a single dose of the RSV vaccine at dosage #1
Intervention: RSV vaccine MV-012-968 (dosage #1) (Biological)
RSV Vaccine: Dosage Group #2
Participants in this group will receive a single dose of the RSV vaccine at dosage #2
Intervention: RSV vaccine MV-012-968 (dosage #2) (Biological)
Outcomes
Primary Outcomes
Serious adverse events (SAEs)
Time Frame: Vaccination through study completion, an average of 6 months
Frequency of SAEs will be measured, categorized by vaccine-relatedness. SAEs are AEs, whether considered causally related to the investigational vaccine or not, that threaten life or result in any of the following: death, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or congenital anomaly/birth defect.
Medically attended adverse events (MAEs)
Time Frame: Vaccination through study completion, an average of 6 months
Frequency of MAEs will be measured, categorized by vaccine-relatedness. MAEs are AEs, whether considered causally related to the investigational vaccine or not, with unscheduled medically attended visits, such as urgent care visits, acute primary care visits, emergency department visits, or other previously unplanned visits to a medical provider. Scheduled medical visits such as routine physicals, wellness checks, 'check-ups', and vaccinations, are not considered MAEs.
Unsolicited AEs
Time Frame: Immediate post-vaccination period
Frequency of unsolicited AEs will be measured, categorized by severity. Unsolicited AEs are any untoward medical occurrences in a participant administered the investigational vaccine, regardless of causal relationship to the investigational vaccine. Unsolicited AEs can include unfavorable and unintended signs (including abnormal laboratory findings), symptoms, or diseases temporally associated with the use of the investigational vaccine.
Solicited adverse events (AEs)
Time Frame: Immediate post-vaccination period
Frequency of solicited AEs will be measured, categorized by severity. Solicited AEs are predefined AEs that can occur after vaccine administration.
Secondary Outcomes
- Change in serum RSV-specific neutralizing antibody (nAb) titers(Baseline through study completion, an average of 6 months)
- Change in serum RSV F-specific binding antibody titers(Baseline through study completion, an average of 6 months)
- Change in mucosal RSV F-specific binding antibody titers(Baseline through study completion, an average of 6 months)
- Potential vaccine virus shedding(Baseline through 2 months)